Vanda Pharmaceuticals Inc. (VNDA): Total Assets
$488.95M
As of 2025-12-31
$412.47M
As of 2026-06-30
-8.3%
3-year compound annual growth
-1.7%
5-year compound annual growth
+8.7%
10-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $488.95M | -25.5% | 2026-02-12, Balance as of period end |
| 2024-12-31 | $656.20M | +1.2% | 2026-02-12, Balance as of period end |
| 2023-12-31 | $648.44M | +2.2% | 2025-02-14, Balance as of period end |
| 2022-12-31 | $634.25M | +6.8% | 2024-02-08, Balance as of period end |
| 2021-12-31 | $593.79M | +11.3% | 2023-02-09, Balance as of period end |
| 2020-12-31 | $533.46M | +10.3% | 2022-02-24, Balance as of period end |
| 2019-12-31 | $483.75M | +45.7% | 2021-02-11, Balance as of period end |
| 2018-12-31 | $332.13M | +61.7% | 2020-02-26, Balance as of period end |
| 2017-12-31 | $205.43M | -2.4% | 2019-02-19, Balance as of period end |
| 2016-12-31 | $210.37M | -1.3% | 2018-02-15, Balance as of period end |
| 2015-12-31 | $213.05M | +24.1% | 2017-02-17, Balance as of period end |
| 2014-12-31 | $171.70M | +19.8% | 2016-02-12, Balance as of period end |
| 2013-12-31 | $143.35M | +5.8% | 2015-03-13, Balance as of period end |
| 2012-12-31 | $135.45M | -25.8% | 2014-02-25, Balance as of period end |
| 2011-12-31 | $182.62M | -14.3% | 2013-02-26, Balance as of period end |
| 2010-12-31 | $213.10M | n/a | 2012-03-09, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Vanda Pharmaceuticals Inc. (VNDA) | 2025-12-31 | $488.95M | -25.5% |
| Amarin Corp PLC (AMRN) | 2025-12-31 | $670.77M | -2.1% |
| IDEAYA Biosciences, Inc. (IDYA) | 2025-12-31 | $1.11B | -1.3% |
| Puma Biotechnology, Inc. (PBYI) | 2025-12-31 | $216.30M | +1.4% |
| Anaptysbio, Inc (ANAB) | 2025-12-31 | $364.39M | -24.7% |
| Akebia Therapeutics, Inc. (AKBA) | 2025-12-31 | $376.56M | +70.6% |
| Keros Therapeutics, Inc. (KROS) | 2025-12-31 | $338.02M | -45.1% |
| Rhythm Pharmaceuticals, Inc. (RYTM) | 2025-12-31 | $480.20M | +22.4% |
| Arcus Biosciences, Inc. (RCUS) | 2025-12-31 | $1.14B | -1.0% |
Compare VNDA, AMRN, IDYA, PBYI side by side · Screen every company in Pharmaceutical Preparations ↗